Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/183760
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oñate, Guadalupe | - |
dc.contributor.author | Bataller, Alex | - |
dc.contributor.author | Garrido, Ana | - |
dc.contributor.author | Hoyos Colell, Montserrat | - |
dc.contributor.author | Arnan, Montserrat | - |
dc.contributor.author | Vives, Susana | - |
dc.contributor.author | Coll, Rosa | - |
dc.contributor.author | Tormo, Mar | - |
dc.contributor.author | Sampol, Antonia | - |
dc.contributor.author | Escoda, Lourdes | - |
dc.contributor.author | Salamero, Olga | - |
dc.contributor.author | Garcia, Antoni | - |
dc.contributor.author | Bargay, Joan | - |
dc.contributor.author | Aljarilla, Alba | - |
dc.contributor.author | Nomdedeu, Josep F. | - |
dc.contributor.author | Esteve, Jordi | - |
dc.contributor.author | Sierra, Jorge | - |
dc.contributor.author | Pratcorona, Marta | - |
dc.date.accessioned | 2022-03-04T11:22:55Z | - |
dc.date.available | 2022-03-04T11:22:55Z | - |
dc.date.issued | 2021-09-13 | - |
dc.identifier.issn | 2473-9537 | - |
dc.identifier.uri | http://hdl.handle.net/2445/183760 | - |
dc.description.abstract | The negative prognostic impact of internal tandem duplication of FLT3 (FLT3-ITD) in patients with acute myeloid leukemia with mutated NPM1 (AML-NPM1) is restricted to those with a higher FLT3-ITD allelic ratio (FLT3(high); >= 0.5) and considered negligible in those with a wild-type (FLT3WT)/low ITD ratio (FLT3low). Because the comutation of DNMT3A (DNMT3A(mut)) has been suggested to negatively influence prognosis in AMLNPM1, we analyzed the impact of DNMT3A(mut) in FLT3-ITD subsets (absent, low, and high ratios). A total of 164 patients diagnosed with AML-NPM1 included in 2 consecutive CETLAM protocols and with DNMT3A and FLT3 status available were studied. Overall, DNMT3A(mut) status did not have a prognostic impact, with comparable overall survival (P = .2). Prognostic stratification established by FLT3-ITD (FLT3WT = FLT3low > FLT3(high)) was independent of DNMT3A(mut) status. Measurable residual disease (MRD) based on NPM1 quantitative polymerase chain reaction was available for 94 patients. DNMT3A(mut) was associated with a higher number of mutated NPM1 transcripts after induction (P = .012) and first consolidation (C1; P < .001). All DNMT3A(mut) patients were MRD+ after C1 (P < .001) and exhibited significant MRD persistence after C2 and C3 (MRD+ vs MRD-; P = .027 and P = .001, respectively). Finally, DNMT3A(mut) patients exhibited a trend toward greater risk of molecular relapse (P = .054). In conclusion, DNMT3A(mut) did not modify the overall prognosis exerted by FLT3-ITD in AML-NPM1 despite delayed MRD clearance, possibly because of MRD-driven preemptive intervention. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | American Society of Hematology | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2020004136 | - |
dc.relation.ispartof | Blood Advances, 2021, vol 6, num 3, p. 882-890 | - |
dc.relation.uri | https://doi.org/10.1182/bloodadvances.2020004136 | - |
dc.rights | cc by-nc-nd (c) Oñate, Guadalupe et al, 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Leucèmia mieloide | - |
dc.subject.classification | Enzims | - |
dc.subject.other | Myeloid leukemia | - |
dc.subject.other | Enzymes | - |
dc.title | Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1 | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2022-03-03T11:26:13Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34516636 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
advancesadv2020004136.pdf | 1.25 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License